Latest Data & Signals Issued

Signal Type Signal Value Data
Score -2.450 34 days ( 32.88 % )
Last Price $5.47 4.99 %
High/ Low $5.21 - $5.67 7.49%
Chg 7 Days 2.24 % $5.35 $5.47
Chg 30 Days -24.86 % $7.28 $5.47
Chg 12 mos -30.50 % $7.87 $5.47
Trend - 3 mos -26.15 % Width: 70.92 %
Trend - 12 mos -14.46 % Width: 106.65 %
Pred. range - 3 mos $3.81 - $6.51 -30.36 % - 19.04 %
Pred. range - 12 mos $4.45 - $9.20 -18.64 % - 68.13 %
Short MA avg 3 mos Buy Apr 30, 2024 - 2 days
Long MA avg 3 mos Sell Mar 13, 2024 - 35 days
Short/Long MA avg 3 mos Sell Mar 19, 2024 - 31 days
Short MA avg 12 mos Sell Mar 11, 2024 - 37 days
Long MA avg 12 mos Sell Mar 11, 2024 - 37 days
Short/Long MA avg 12 mos Sell Jan 30, 2024 - 65 days
Pivot Short Buy Apr 30, 2024 - 2 days
Bollinger Buy Jan 05, 2024 - 81 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Editas Medicine, Inc

Editas Medicine Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, whic... EDIT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT